31206-25-4

Upstream product

• 99-35-4 1,3,5-trinitrobenzene 
• 99-65-0 meta-dinitrobenzene 
• 618-87-1 3, 5-dinitroaniline 
• 27886-97-1 3,5-dinitrobenzenediazonium chloride 

Downstream Products

• 102169-77-7 3,5-dinitro-benzenesulfonic acid methyl ester 
• 50825-96-2 3,5-dinitrobenzenesulfonamide 
• 102871-65-8 bis(3,5-dinitrophenyl)disulfide 
• 1316065-93-6 3-amino-N-methyl-5-nitrobenzenesulfonamide 
• 1316065-92-5 3-chloro-N-methyl-5-nitrobenzenesulfonamide 
• 1316065-94-7 3-amino-5-chloro-N-methylbenzenesulfonamide 
• 1316065-99-2 3-(dimethylamino)-N-methyl-5-nitrobenzenesulfonamide 
• 1316065-96-9 3-amino-5-(dimethylamino)-N-methylbenzenesulfonamide 
• 1445879-74-2 N-cyclopropyl-4-((3-(4-fluorophenoxy)-5-sulfamoylphenyl)amino)-7-(4-methoxypyrimidin 5-yl)quinoline-3-sulfonamide 
• 1445880-81-8 7-bromo-N-cyclopropyl-4-(3-(4-fluorophenoxy)-5-sulfamoylphenylamino)quinoline-3-sulfonamide 
• 1445879-75-3 N-cyclopropyl-4-((3-(4-fluorophenoxy)-5-sulfamoylphenyl)amino)-7-(pyrimidin-5-yl)quinoline-3-sulfonamide 
• 1445880-82-9 3-(4-fluorophenoxy)-5-nitrobenzenesulfonamide 
• 1445880-83-0 3-amino-5-(4-fluorophenoxy)benzenesulfonamide 
• 1445879-76-4 N-cyclopropyl-7-(3,5-dimethyl-1H-pyrazol-4-yl)-4-((3-(4-fluorophenoxy)-5-sulfamoylphenyl)amino)quinoline-3-sulfonamide 

Relevant academic research and scientific papers

Synthesis of sulfonimide-based dendrimers and dendrons possessing mixed 1?→?2 and 1?→?4 branching motifs

The synthesis of dendrimers and a chlorosulfo-dendron possessing a unique combination of 1 → 2 and 1 → 4 branching types is described. The procedure consists of a two-step preparation of 3,5-dinitrobenzene-1-sulfonyl chloride, which was used for the persu

Novel dye intermediate, preparation method thereof, novel dyes and preparation methods of novel dyes

The invention relates to the field of reactive dyes, and particularly discloses a novel dye intermediate, a preparation method thereof, novel dyes and preparation methods of the novel dyes. The preparation method of the novel dye intermediate comprises the following steps: a, chlorosulfonation; b, reduction; c, condensation; d, hydrogenation reduction; and e, esterification and dilution. The novel dyes provided by the invention have the advantages of higher degree of dyeing, higher fixation rate, better color fastness and more environment-friendly production process.

AROMATIC SULFONAMIDE DERIVATIVES AND THEIR USE AS ANATAGON I STS OR NEGATIVE ALLOSTERIC MODULATORS OF P2X4

Substituted aromatic sulfonamides of formula (I), pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease.

Design and syntheses of anti-tuberculosis agents inspired by BTZ043 using a scaffold simplification strategy

Tuberculosis (TB), a disease caused by Mycobacterium tuberculosis (Mtb), is a global public health concern because of the emergence of various resistant strains. Benzothiazin-4-ones (BTZs), represented by BTZ043, are a promising new class of agents for the treatment of tuberculosis and have been shown to kill Mtb in vitro, ex vivo, and in mouse models of TB. Herein we report the design and syntheses of nitroaromatic sulfonamide, reverse-amide, and ester classes of anti-TB agents using a scaffold simplification strategy based on BTZ043. The presented work explores the effect of functional groups such as sulfonamides, reverse-amides, and esters that are attached to the nitroaromatic rings on their anti-TB activity. The in vitro activity of the compounds evaluated against the H37Rv strain of Mtb show that nitroaromatic sulfonamides and nitrobenzoic acid esters with two nitro substituents were most active and highlights the importance of the electronic character (electron deficient aromatic ring) of the nitroaromatic ring as a central theme in these types of nitroaromatic anti-TB agents.

CHEMICAL COMPOUNDS

The invention is directed to substituted quinoline derivatives. Specifically, the invention is directed to compounds according to Formula I: wherein R, R1, R2, R3 and R4 are defined herein. The compounds of the invention are inhibitors of lactate dehydrogenase A and can be useful in the treatment of cancer and diseases associated with tumor cell metabolism, such as cancer, and more specifically cancers of the breast, colon, prostate and lung. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting lactate dehydrogenase A activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

COMPOUNDS AND METHODS

Disclosed are compounds having the formula (I): wherein R1, R2, R3, R4, R5, and R6 are as defined herein, and methods of making and using the same.

Inhibitors of the tyrosine kinase EphB4. Part 2: Structure-based discovery and optimisation of 3,5-bis substituted anilinopyrimidines

Crystallographic studies of a range of 3-substituted anilinopyrimidine inhibitors of EphB4 have highlighted two alternative C-2 aniline conformations and this discovery has been exploited in the design of a highly potent series of 3,5-disubstituted anilin

Isothiazoles as active-site inhibitors of HCV NS5B polymerase

Isothiazole analogs were discovered as a novel class of active-site inhibitors of HCV NS5B polymerase. The best compound has an IC50 of 200 nM and EC50 of 100 nM, which is a significant improvement over the starting inhibitor (1). The X-ray complex structure of 1 with HCV NS5B was obtained at a resolution of 2.2 A, revealing that the inhibitor is covalently linked with Cys 366 of the 'primer-grip'. Furthermore, it makes considerable contacts with the C-terminus, β-loop, and more importantly, to the active-site of the enzyme. The uniqueness of this binding mode offers a new insight for the rational design of novel inhibitors for HCV NS5B polymerase.

Dinitrobenzenesulfonamides

A compound of the formula: STR1 wherein: n is an integer 2,3,4, or 5; R1 is hydrogen or an alkyl group; and R2 and R3 are defined as follows: R2 is hydrogen or an alkyl group; R3 is hydrogen or an alkyl group; or R2 and R3 together form a heterocyclic ring, e.g. piperidine, pyrrolidine. The compounds have high radiosensitizing activity, and act as agents toxic to hypoxic cells in the absence of radiation.